Real-Life Safety and Effectiveness of Dupilumab in Patients With Concomitant Malignancies: A Case Series

Real-Life Safety and Effectiveness of Dupilumab in Patients With Concomitant Malignancies: A Case Series

Authors

  • Luigi Gargiulo Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
  • Carlo Alberto Vignoli Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
  • Andrea Cortese Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
  • Luciano Ibba Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
  • Antonio Costanzo Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
  • Alessandra Narcisi Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

References

Costanzo A, Amerio P, Asero R, et al. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Ital J Dermatol Venerol. 2022;157(1):1-12. doi:10.23736/S2784-8671.21.07129-2

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. Drug Saf. 2018;41(5):489-509. doi:10.1007/s40264-017-0636-9

Shirley M. Dupilumab: First Global Approval. Drugs. 2017;77(10):1115-1121. doi:10.1007/s40265-017-0768-3

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. Drug Saf. 2018;41(5):489-509. doi:10.1007/s40264-017-0636-9

Siliquini N, Giura MT, Viola R, et al. Atopic dermatitis, dupilumab and cancers: a case series. J Eur Acad Dermatol Venereol. 2021;35(10):e651-e652. doi:10.1111/jdv.17264

Fowler E, Rosen J, Lev-Tov H, Yosipovitch G. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis. Acta Derm Venereol. 2019;99(10):899-900. doi:10.2340/00015555-3201

Downloads

Published

2023-07-31

Issue

2023 Vol 13, No 3 | July

Section

Research Letter

License

Copyright (c) 2023 Carlo Alberto Vignoli

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
Gargiulo L, Vignoli CA, Cortese A, Ibba L, Costanzo A, Narcisi A. Real-Life Safety and Effectiveness of Dupilumab in Patients With Concomitant Malignancies: A Case Series. Dermatol Pract Concept. 2023;13(3):e2023143. doi:10.5826/dpc.1303a143

Share

Crossref
Scopus
Google Scholar
Europe PMC